Gansu Pu An Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation brepizole orodispersible film (specification: 2 mg, developed by Gansu Puan Pharmaceutical Co., Ltd.) and the reference preparation brepizole tablets (RXULTI®, specification: 2 mg, produced by Otsuka Pharmaceutical Netherlands.B.V) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of brepizole orodispersible film in healthy subjects after a single oral administration in the fasting and fed state.